Physician profile
Gerald J Lee
NPI 1982692745
$12,034.49
in general payments reported to CMS, 2019-2025
77 companies · $2,413 in 2025
The $2,413 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $1,137 · 2021: $1,375 · 2022: $1,748 · 2023: $1,744 · 2024: $2,037 · 2025: $2,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,164 · Education: $30.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,163.61 |
| Education | $30.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,725.33 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $1,501.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $662.23 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $578.65 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $558.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $550.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $510.72 | 2019-2025 | Steglatro, Capvaxive, Belsomra |
| Pfizer INC. | $358.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $298.87 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.69 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $232.72 | 2023-2025 | |
| Janssen Biotech, INC. | $210.79 | 2022-2025 | Simponi, Simponi Aria, Stelara |
| Abbott Laboratories | $189.48 | 2022-2024 | Eterna, Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $187.48 | 2019-2025 | Zoryve |
| Exact Sciences Corporation | $183.19 | 2023-2025 | Cologuard Collection Kit |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.